Browse News
Filter News
Found 486,187 articles
-
The particular areas where sales jobs will be thinned are primary care, disease-focused endocrinology and hospital chronic care.
-
Immuno-oncology and gene therapy has been a hot field for the last few years, and the approval of the first CAR-T therapies has only set the kindling ablaze.
-
ADC Therapeutics announced it had raised $200M through an oversubscribed private placement.
-
The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF).
-
The FDA based its decision on data from the COMBI-AD Phase III trial.
-
Two privately-held biotechs have merged to tackle recurrent C. difficile infections.
-
In order to meet growing demand for insulin, pharma giant Eli Lilly said it will invest $72M to expand insulin manufacturing capabilities at one of its Indianapolis facilities.
-
DBV's share price crumbled over the weekend after its Phase III peanut allergy trial failed to show a statistically significant response against placebo.
-
TPG Capital has acquired all the outstanding shares of Exactech common stock for $42 per share.
-
Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation C...
10/23/2017
The research collaboration and license agreement was originally initiated in October 2015. -
If J&J's going to keep rewarding investors, it's going to need these top drugs to continue racking up sales.
-
Agenus Creates New Cell Therapy Subsidiary Named AgenTus Therapeutics
10/23/2017
Agenus today announced the launch of a subsidiary company for its cell therapy business, AgenTus Therapeutics.
-
Easton Pharmaceuticals Announces Final Payment Completing $1.3M JV Agreement With Alliance Group
10/23/2017
Easton has advanced its final payment, completing a total payment of $1.3 Million CDN to 1124123 Ontario Limited.
-
Biogen and Eisai Expand Alzheimer's R&D Collaboration
10/23/2017
Under the deal, Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta antibody for patients with Alzheimer’s disease.
-
GlaxoSmithKline's Shingrix Approved in the U.S. for Prevention of Shingles in Adults Aged 50 and ...
10/23/2017
Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses. -
FDA Approves AstraZeneca's New Easy-to-Use, Once-weekly BYDUREON BCise Injectable Medicine for Pa...
10/23/2017
BYDUREON BCise has a unique, continuous-release microsphere delivery system designed to provide consistent therapeutic levels of the active ingredient. -
Real-World Study Shows Merck's ZEPATIER (Elbasvir and Grazoprevir) Resulted in High Rates of Sustained Virologic Response in Patients With Chronic Hepatitis C Infection Who Have Chronic Kidney Disease
10/23/2017
These findings will be presented today at The Liver Meeting 2017 taking place in Washington, D.C.
-
Boehringer Ingelheim Release: Ofev Demonstrates Consistent Long-Term Efficacy in IPF Regardless of Baseline Lung Function
10/23/2017
Boehringer Ingelheim announced today the presentation of a new analysis on the use of Ofev (nintedanib) in treating people with idiopathic pulmonary fibrosis (IPF) at the 2017 CHEST Annual Meeting.
-
Tigenix Granted Orphan Drug Designation From the U.S. FDA for Cx601
10/23/2017
TiGenix started a global pivotal Phase III clinical trial in the first half of 2017.
-
Eiger Announces Positive Phase II Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus Infection at the AASLD Meeting
10/23/2017
Eiger BioPharma today announced positive interim 24-week data with pegylated interferon lambda in the Phase II LIMT HDV Study presented at the AASLD meeting in Washington DC.